Masimo (NASDAQ:MASI) Releases Q4 2024 Earnings Guidance

Masimo (NASDAQ:MASI) updated its fourth quarter 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.350-1.500 for the period, compared to the consensus estimate of 1.410. The company issued revenue guidance of $581.0 million-$611.0 million, compared to the consensus revenue estimate of $607.4 million. Masimo also updated its FY24 guidance to $3.95-$4.10 EPS.

Masimo Stock Performance

Shares of NASDAQ:MASI traded up $4.17 during trading on Tuesday, hitting $151.56. 1,309,932 shares of the company traded hands, compared to its average volume of 675,776. The company has a quick ratio of 1.15, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The business’s fifty day moving average is $130.02 and its 200-day moving average is $125.22. The stock has a market capitalization of $8.06 billion, a price-to-earnings ratio of 103.10 and a beta of 0.97. Masimo has a one year low of $75.36 and a one year high of $153.93.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The firm had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. During the same period in the prior year, the business earned $0.62 EPS. The firm’s revenue was up 9.0% on a year-over-year basis. As a group, equities analysts predict that Masimo will post 3.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating on shares of Masimo in a research report on Friday, October 18th. BTIG Research lifted their price target on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a report on Friday, September 20th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $145.33.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.